AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03816579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO-A
Description: 30 g of beef protein will be consumed at each meal
Study NCT03803267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: For each side, the eighth thoracic transverse process will be identified by a linear US transducer (HFL38_10-5 MHz), puncture will be performed in the plane in the craniocaudal direction until the needle contacts the transverse process, and 20 ml of bupivacaine 0.25% and 4 mg dexamethasone will be injected visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesirable motor weakness will be recorded as a side effect.
Study NCT03803267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: For each side, shamrock sign with three leaves (psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process of the L4 vertebral body) will be identified by a curved array US transducer (6-2MHz), puncture will be performed in-plane, the needle will be advanced through the quadratus lumborum muscle penetrating the ventral proper fascia of the quadratus lumborum muscle, and 20 mL of bupivacaine 0.25% and 4 mg dexamethasone will be injected in that space visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesired motor weakness will be recorded as a side effect
Study NCT03803267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol (2 mg/kg)
Study NCT04343729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Sodium Succinate
Description: injectable solution at a dose of 0.5mg/kg
Study NCT04343729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: injectable saline solution
Study NCT02338037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo tumor resection
Study NCT02338037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT02338037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV
Study NCT02338037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microdialysis
Description: Undergo intracerebral microdialysis
Study NCT02338037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT04669613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CUDI
Description: Analysis of the CEUS data by means of Contrast ultrasound dispersion imaging
Study NCT02400190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endocrine therapy alone without radiotherapy
Description: Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
Study NCT00753987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: 5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
Study NCT03673202 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cx bladder Monitor test
Description: Cxbladder Monitor is a non-invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma and also two clinical variables (whether the previous tumor was primary or recurrent and the time since the previous tumor was resected).
Study NCT04484064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence program
Description: This program combines adherence evaluation using an electronic monitor (MEMS®) and feedback with repeated medication adherence interviews with the pharmacist.
Study NCT03109717 — intervention group
Intervention type: DRUG
Intervention: Monoamine Oxidase Inhibitor (MAOI)
Description: Monoamine Oxidase Inhibitor
Study NCT02144324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem Appliance
Description: We are going to use a modified version of the Tandem Appliance
Study NCT01576510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Description: Prolonged Exposure (PE) therapy consists of ten 90-minute sessions. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation. The therapist helps the patient cognitively restructure his/her experience of the traumatic event. Each week the narrative is elaborated, becoming more detailed and exhaustive, until the patient habituates to it, extinguishing the anxiety it formerly aroused.
Study NCT02373813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept pre-filled syringe subcutaneous injection
Description: etanercept for injection in pre-filled syringes
Study NCT02373813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral methotrexate
Description: During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.~During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules.
Study NCT03816579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO-B
Description: 30 g of complementary proteins will be consumed at each meal
Study NCT02373813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for etanercept subcutaneous injection
Description: etanercept placebo for injection in pre-filled syringes
Study NCT02373813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for methotrexate
Description: methotrexate placebo capsules
Study NCT02373813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid (non-investigational product)
Description: Folic acid 5 to 7 mg per week as per investigator judgment or according to local standard of care.
Study NCT03344289 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Participants will be randomized towards colonoscopy withdrawal with either LCI or HD-WLE
Study NCT03344289 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Participants will be randomized towards colonoscopy withdrawal with either LCI or HD-WLE
Study NCT03279198 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TIWeb
Description: Intervention: TIWeb program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
Study NCT03279198 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CSC
Description: Intervention: CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
Study NCT03279198 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: UC
Description: Intervention: The usual care group received usual care that varies dependent upon the practice setting.
Study NCT03279198 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TIWeb+CSC
Description: Intervention: TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
Study NCT02547805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177
Description: ALLN-177 7,500 units (5 capsules) PO TID with meals
Study NCT02547805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 5 capsules PO TID with meals
Study NCT01746394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents as Teachers Enhanced
Description: Participants will receive the same monthly Parents as Teachers (PaT) lessons and materials at each home visit as the PaT arm. Additionally, these mothers will receive the enhanced nutrition and physical activity lessons and materials which will follow the family well-being format of the PaT lessons. The StartSmart lessons will focus on healthy gestational weight gain, diet, physical activity, breastfeeding, weight management, healthy eating, food shopping, meal preparation, physical activity, proper infant feeding, and infant activity time.
Study NCT01746394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parents as Teachers
Description: Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
Study NCT01746394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents as Teachers
Description: Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
Study NCT00788424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS101 Cream
Description: 4% AS101 Cream or Placebo cream, twice a day for 12 weeks
Study NCT03816579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO-C
Description: 30 g of complementary proteins will be consumed over 24 hours
Study NCT01933555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment Program
Study NCT01974921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALAIR Catheter. Radiofrequency system.
Description: Radiofrequency with Alair Catheter trhough flexible bronchoscopy in three different sessions (right lower lobe, left lower lobe, both upper lobes).
Study NCT03831438 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AVID200
Description: Intravenous infusion of AVID200 Q2 weeks for 3 doses
Study NCT06486935 — intervention group
Intervention type: DEVICE
Intervention: IoT sensors
Description: The proposed assistive Activities of Daily Living (ADL) monitoring system consists of ambient infrared sensors embedded seamlessly into the living environment, and a visualization app. Multimodality sensors with wireless data transmission capability will be installed at different locations (e.g. bedroom, kitchen, toilet, bathroom, living room, etc.) to monitor and detect the activities performed by individual elderly, such as cooking, sleeping, going to the bathroom, going out of the apartment or potential wandering, bathroom falls, etc. In addition, a micro-bend fiber optic pressure sensor mat will be placed unobtrusively below the bed mattress to measure the elderly's heart and respiratory rates during sleep. This mat helps provide information on the quality of sleep and sleep-wake rhythms of the elderly with sleep disorders. The collected data will then be transferred through a secured gateway with Raspberry Pi to a dedicated server for data processing and analysis.
Study NCT06486935 — intervention group
Intervention type: OTHER
Intervention: Traditional/Manual elderly monitoring
Description: Traditional elderly care without the use of IoT sensors.
Study NCT02548793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education: CPR Training via Mobile App
Description: Using a mobile app to train users on chest-compression only CPR. Subjects will be encouraged to share the app with family and friends.
Study NCT02460588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2
Study NCT02460588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
Study NCT01222858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Activity Education
Description: Education about behavioral modification of eating and activity habits for weight loss.
Study NCT01222858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Activity Education
Description: Education about behavioral modification of eating and activity habits for weight loss.
Study NCT01222858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring with Feedback
Description: Participants self-monitor diet and activity behaviors, which are submitted via a website. Automated feedback on the self-monitoring record is provided to participants.
Study NCT00270829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Description: Drug given intrarenally or placebo
Study NCT02460588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid (prednisolone)
Description: All patients will receive non experimental medication with high dose of corticosteroid.
Study NCT02288143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COOL-COS
Description: Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:~* Oral clomiphene citrate: 100 mg/day until the day of the triggering.~* Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~* hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.~The triggering will be performed using urinary hCG (5,000 IU subcutaneous).~* 1-2 days after the identification of one follicle ≥ 17 mm~* 0-1 days after the identification of one follicle ≥ 19 mm.
Study NCT01133561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: actozone A
Description: pioglitazone 30 mg tablet , once daily dose for 10 weeks
Study NCT01133561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: actozone B
Description: one tablet of vehicle without active ingredient pioglitazone
Study NCT00760214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
Study NCT00760214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
Study NCT00760214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
Study NCT02005432 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal Ranibizumabe
Description: Intravitreal injection 0,05ml Ranibizumabe
Study NCT02005432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumabe
Description: Intravitreal injection 0,05ml Ranibizumabe
Study NCT02005432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Ranibizumabe
Description: Intravitreal injection 0,05ml Ranibizumabe
Study NCT02005432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panfotocoagulation (PASCAL)
Study NCT02005432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: panfotocoagulation (PRP) single shoot (ETDRS)
Study NCT05254223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiinflammatory Diet
Description: The intervention group is recommended to follow a diet, inspired in mediterranean diet, rich in anti-inflammatory foods. They are provided with a table with the recommended foods as well as the frequency of daily/weekly/biweekly consumption.
Study NCT05254223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: The control group is recommended to follow their usual diet. Only in the case of detecting a serious nutritional problem the participant is recommended to correct it with the appropriate advice of the nutritionist.
Study NCT04365257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Participants in this arm will receive the study drug as outlined in the arm description.
Study NCT04365257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants in this arm will receive standard of care.
Study NCT02854176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Somatosensory electrical stimulation
Study NCT02854176 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Study NCT02818231 — intervention group
Intervention type: OTHER
Intervention: Brushing of the olfactory cleft
Description: Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability
Study NCT00518973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
Study NCT00518973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
Study NCT00430430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High MUFA dietary portfolio
Description: high monounsaturated fat background diet to dietary portfolio
Study NCT00430430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low MUFA dietary portfolio
Description: low monounsaturated fat background diet to dietary portfolio
Study NCT01454115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 0.3 mg, Once daily, once
Study NCT01454115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 1.5 mg, Once daily, once
Study NCT01454115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 5.0 mg, Once daily, once
Study NCT01454115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 15.0 mg, Once daily, once
Study NCT01454115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 50 mg, Once daily, once
Study NCT01454115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 100 mg, Once daily, once
Study NCT01454115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 200 mg, Once daily, once
Study NCT01454115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 400 mg, Once daily, once
Study NCT01454115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Capsule, Oral, 50 mg, Once daily, once